Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

RAC GS Braindumps


Published on

Prepare your RAPS (Regulatory Affairs Professionals Society) exam RAC GS (Regulatory Affairs Certification Global Scope) by Exams4sure. Study of drugs and meditation is not an easy job at all you need to focus on it to pass the exam on the first attempt. You can easily prepare by Exams4sure RAC GS Braindumps. We provide you authentic RAC GS Exam Questions along with RAC GS Test Engine. It will help you in preparation. Visit us today and get 20% discount on RAC GS Dumps. Our chat support will help you to sort our your problems. For more information visit us
or email us

Published in: Education
  • Be the first to comment

  • Be the first to like this

RAC GS Braindumps

  1. 1. First you need to know what is RAC GS? And how much this certification beneficent for you?
  2. 2. Regulatory Affairs Certification (RAC) US Exam Regulatory Affairs Certification (RAC) An individual certification for our global industry. ... RAC (Global): Knowledge and critical thinking skills r elated to the international practice of regulatory affairs, with special a ttention paid to global standards from ICH, GHTF (through IMDRF) Content by
  3. 3. GS/RAC GS-exam-questions-dumps.html
  4. 4. Question No 1: The Food and Drug Administration Modernization Act (FDAMA) established two types of for mal early collaboration meetings. Which of the following is one of those meetings? A. PDP meeting B. Agreement Meeting C. Pre-IDE meeting D. Type A meeting Answer: B
  5. 5. Question No 2: A sponsor intends to submit a Special Protocol Assessment (SPA) request for a clinical trial t hat will form the primary basis of an efficacy claim in an NDA. Which of the following is TRUE? A. The sponsor should submit the SPA request within 30 days following the start of the trial t o expedite FDA feedback B. An SPA provides an opportunity to focus on general drug development issues C. The SPA request will be handled as a request for a Type B meeting D. A sponsor can submit a revised protocol while the agency is reviewing an earlier version of the same protocol Answer: D
  6. 6. Question No 3: Devices that are exempt from premarket notification are: A. All Class I devices B. Some Class I devices C. Most Class I devices and some Class II devices D. All Class I devices and some Class II devices Answer: C
  7. 7. Question No 4: Your company wishes to seek approval of a combination of individually approved anti-hype rtensive and anti-diabetic drugs. However, there is no Reference Listed Drug (RLD) for the p roposed combination. Which of the following regulatory pathways is most applicable? A. 505(b)(2) B. 510(k) C. 505(b)(1) D. 505(j) Answer: A
  8. 8. Question No 5: The following applies to autologous chondrocytes expanded in vitro for the repair of cartila ge defects: A. Regulated under Section 351 of the Public Health Service Act and no premarket approval r equired B. Regulated under Section 351 of the Public Health Service Act and premarket approval requ ired C. Regulated under Section 361 of the Public Health Service Act and no premarket approval r equired D. Regulated under Section 361 of the Public Health Service Act and premarket approval requ ired Answer: B
  9. 9. Question No 6: Which of the following is the best regulatory pathway for drugs containing similar active ing redients as a previously approved drug for a new indication? A. 505(j) ANDA B. 505(b)(1) NDA C. 505(b)(2) NDA D. 505 (d) Substantial Evidence of Effectiveness Answer: C
  10. 10. Question No 7: In order to be approved by FDA, a generic drug must be therapeutically equivalent to the br anded product with the exception of: A. Dosage Form B. Route of Administration C. Inactive Ingredient(s) D. Labeling Answer: C
  11. 11. Question No 8: Your company is developing a New Chemical Entity (NCE) drug to treat Glioblastoma multif orme, which is the deadliest and most common form of malignant brain tumor. The compo und team has designed a pivotal study protocol with a clinically meaningful and well-establi shed primary endpoint. To increase the likelihood FDA will agree with the study design, which of the following regulatory strategies has to occur prior to initiating the pivotal study? A. Request Fast Track designation B. Request priority review C. Request approval under Subpart H, Accelerated Approval of New Drugs for Serious or Life Threatening Illness D. Request Special Protocol Assessment Answer: D
  12. 12. Question No 9: Which federal law made it illegal for physicians being reimbursed by federally funded progr ams to prescribe or recommend that the patient use a particular manufacturer's medical pr oducts when the doctor receives payment from that manufacturer? A. Medicare and Medicaid Patient Protection Act of 1987 B. Food, Drug, and Cosmetic Act of 1938 (FD&C Act) C. Food and Drug Administration Modernization Act of 1997 (FDAMA) D. Food and Drug Administration Amendments Act of 2007 (FDAAA) Answer: A
  13. 13. Question No 10: Company Z selected a proprietary name for its new molecular entity, currently in developm ent. The NDA will be submitted in six months. All of the following are Relevant to the propri etary name EXCEPT: A. The request for proprietary name approval may be submitted with the NDA. B. The proprietary name submission package may be Submitted up to one month after NDA s ubmission. C. The request for proprietary name approval may be submitted prior to the NDA. D. FDA will communicate to the applicant a tentative acceptance or non-acceptance of the pr oposed proprietary name submitted with the NDA within 90 days of the receipt of the compl ete submission. Answer: B
  14. 14. Why Choose us? 100% Money Back Guaran tee RAC GS Real Exam Questions Simulatio ns 3 Months Free Updates Valid for World wide 100% Real Exam Questions 100% Passing Assuranc e
  15. 15. Visitus!! 20% off
  16. 16. Thanks FOR Watching